Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.

Diro E, Blesson S, Edwards T, Ritmeijer K, Fikre H, Admassu H, Kibret A, Ellis SJ, Bardonneau C, Zijlstra EE, Soipei P, Mutinda B, Omollo R, Kimutai R, Omwalo G, Wasunna M, Tadesse F, Alves F, Strub-Wourgaft N, Hailu A, Alexander N, Alvar J.

PLoS Negl Trop Dis. 2019 Jan 17;13(1):e0006988. doi: 10.1371/journal.pntd.0006988. eCollection 2019 Jan.

2.

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.

Abongomera C, Diro E, de Lima Pereira A, Buyze J, Stille K, Ahmed F, van Griensven J, Ritmeijer K.

PLoS Negl Trop Dis. 2018 May 25;12(5):e0006527. doi: 10.1371/journal.pntd.0006527. eCollection 2018 May.

3.

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.

PLoS Negl Trop Dis. 2016 Sep 14;10(9):e0004880. doi: 10.1371/journal.pntd.0004880. eCollection 2016 Sep.

4.

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.

Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B.

PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635. doi: 10.1371/journal.pntd.0005635. eCollection 2017 May.

5.

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.

PLoS Negl Trop Dis. 2014 Jan 16;8(1):e2613. doi: 10.1371/journal.pntd.0002613. eCollection 2014.

6.

Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD, Lima MA, Mitra G, Kumar D, Pandey K, Van Geertruyden JP, Boelaert M, Burza S.

Clin Infect Dis. 2015 Oct 15;61(8):1255-62. doi: 10.1093/cid/civ530. Epub 2015 Jun 30.

7.

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

Omollo R, Alexander N, Edwards T, Khalil EA, Younis BM, Abuzaid AA, Wasunna M, Njoroge N, Kinoti D, Kirigi G, Dorlo TP, Ellis S, Balasegaram M, Musa AM.

Trials. 2011 Jun 30;12:166. doi: 10.1186/1745-6215-12-166.

8.

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.

Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.

Clin Infect Dis. 2011 Dec;53(12):e152-8. doi: 10.1093/cid/cir674. Epub 2011 Oct 19.

PMID:
22016502
9.

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.

Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.

Clin Infect Dis. 2006 Aug 1;43(3):357-64. Epub 2006 Jun 20.

PMID:
16804852
10.

Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.

Patole S, Burza S, Varghese GM.

Int J Infect Dis. 2014 Aug;25:204-6. doi: 10.1016/j.ijid.2014.02.015. Epub 2014 Jun 10.

11.

Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.

Faucher JF, Morquin D, Reynes J, Chirouze C, Hoen B, Le Moing V.

Parasitol Int. 2016 Oct;65(5 Pt A):444-6. doi: 10.1016/j.parint.2016.06.009. Epub 2016 Jun 22.

PMID:
27353022
12.

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).

Burza S, Mahajan R, Sinha PK, van Griensven J, Pandey K, Lima MA, Sanz MG, Sunyoto T, Kumar S, Mitra G, Kumar R, Verma N, Das P.

PLoS Negl Trop Dis. 2014 Aug 7;8(8):e3053. doi: 10.1371/journal.pntd.0003053. eCollection 2014 Aug.

13.

Visceral Leishmaniasis and HIV coinfection in East Africa.

Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J.

PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2869. doi: 10.1371/journal.pntd.0002869. eCollection 2014 Jun. Review.

14.

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F.

Lancet. 2011 Feb 5;377(9764):477-86. doi: 10.1016/S0140-6736(10)62050-8. Epub 2011 Jan 20.

PMID:
21255828
15.

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

Burza S, Sinha PK, Mahajan R, Sanz MG, Lima MA, Mitra G, Verma N, Das P.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2611. doi: 10.1371/journal.pntd.0002611. eCollection 2014.

16.

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.

Bull World Health Organ. 1998;76(1):25-32.

17.

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.

Clin Infect Dis. 2008 Oct 15;47(8):1000-6. doi: 10.1086/591972.

PMID:
18781879
18.

Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.

Romero GAS, Costa DL, Costa CHN, de Almeida RP, de Melo EV, de Carvalho SFG, Rabello A, de Carvalho AL, Sousa AQ, Leite RD, Lima SS, Amaral TA, Alves FP, Rode J; Collaborative LVBrasil Group.

PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005706. doi: 10.1371/journal.pntd.0005706. eCollection 2017 Jun.

19.

Current diagnosis and treatment of visceral leishmaniasis.

Mondal S, Bhattacharya P, Ali N.

Expert Rev Anti Infect Ther. 2010 Aug;8(8):919-44. doi: 10.1586/eri.10.78. Review.

PMID:
20695748
20.

Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.

Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D.

Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.

Supplemental Content

Support Center